SRTAW
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Lack of valuation metrics makes it impossible to determine a defensive fair value.
- No P/E ratio available
- No Graham Number calculated
- Price/Book at 0.00
Growth is present but not yet translating to bottom-line viability.
- High YoY revenue growth
- Positive Q/Q momentum
- Inability to convert revenue to operating profit
Long-term price performance is stagnant or declining.
- Consistent -12.5% decline across 1Y, 3Y, and 5Y timeframes
Despite high liquidity, the deterministic health score is at the absolute minimum.
- Low debt levels
- High current ratio
- Piotroski F-Score 0/9
- Negative ROE/ROA
Non-dividend paying entity.
- No dividend history
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SRTAW and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SRTAW
Strata Critical Medical, Inc.
Primary
|
-12.5% | -12.5% | -12.5% | -12.5% | 0.0% | 0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Past News Coverage
Recent headlines mentioning SRTAW from our newsroom.